Advancements offer choice of devices to accommodate more patients, streamline implant procedure, and simplify programming and follow-up care MINNEAPOLIS – July 5, 2006 – Medtronic, Inc. (NYSE: MDT), ...

The FDA has approved an app-based smart programming device used to discreetly and easily control implants treating for overactive bladder (OAB), chronic fecal incontinence (FI) and non-obstructive ...

One of the world's largest medical technology, services and solutions companies, Medtronic plc MDT is making efforts to expand its Pelvic Health & Gastric Therapies business, part of the company's ...

The FDA has approved Medtronic plc’s next-generation sacral neuromodulation (SNM) system, Interstim X, giving patients a recharge-free option with a 10-year+ lifespan. This newest member of the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Medtronic’s MDT neuromodulation business advanced recently with the company receiving FDA’s expanded MRI labeling approval for its InterStim line of sacral neuromodulation (SNM) systems. The updated ...

Smaller, Rechargeable Device Will Provide More Choices for Patients Suffering with Bladder and Bowel Control Issues SureScan™ MRI Leads Will Provide Full-Body MRI Conditional Labeling The rechargeable ...

InterStim Therapy is a sacral neuromodulation therapy from Medtronic. InterStim has been regularly used for urinary incontinence for more than a decade, but recently received additional approval as ...

announced today that newly published data from a multicenter, prospective trial show that sacral nerve stimulation using Medtronic InterStim® Therapy reduced incontinent episodes and increased quality ...